Adam Elsesser: Yes. Really great question. Let me do my best to sort of answer it. The answer of how – what is well over 1,000 submissions mean? The best way to talk about it is it’s we’re closer to the beginning of this launch than we are to the end of this launch, okay? That’s the right way to sort of put it in a frame. We have more to go than has already been accomplished. How fast somebody ramps up? You can’t really – other than maybe one or two cases, you can’t really use a product without it being formally brought on through this process. So that’s the gating item. And so, we have a lot to go to get that going. Once somebody does bring it on, so far, our experience has been that it’s a pretty sticky business. And I think that’s partly what is driving new customers that we haven’t had before to be so interested, because word of mouth, physicians talking to physicians, sharing their experiences that has been very sticky.
So, you tend to have a lot of physicians wanting this to happen as fast as possible so they can start to get using this. And that is why you hear the confidence we have about not just the rest of this year, but going into the prior – the future years as well. We just have not had an experience like this with – where the innovative – the technology itself is driving a scale of adoption or interest like we have seen.
Margaret Kaczor: Okay. And then you’ve referenced yourself kind of the 30%-plus growth as we get into Q4. I know the comps obviously this year are easier than they will be in ’24. But how should we think about that? Because you’ve got the Street at mid-teens, all the commentary you’re saying is so positive, right, both on vascular and neuro. And it just feels like it’s a pretty rapid deceleration, which is not what the commentary is suggesting. So maybe just clear up those two comments versus opportunity? Thanks.
Adam Elsesser: Yes. It’s still summertime. So I hope you don’t mind it. I’m not going to give guidance for 2024 in the middle of summer for 2023. I think you can take our commentary and what we’re sharing about what we have in front of us as the best sign of our confidence. To quantify that down into a percentage is a tough premature at this point. But, that’s not in any way to not be enthusiastic about all three of those products that we’re currently launching.
Margaret Kaczor: Okay. Thanks. I had to try.
Adam Elsesser: I appreciate the effort.
Operator: Your next question is from the line of Joanne Wuensch from Citi. Your line is open.
Unidentified Analyst: Hi, good afternoon. This is Anthony on for Joanne. Thanks for taking our questions. I think last quarter, you called out supply as maybe a headwind or gating factor to Flash update. Just curious if that was the case this quarter again. And then just as a quick follow-up, can you just talk about adoption trends you’re seeing with Flash and peak PE cases versus DVT? Thank you.
Adam Elsesser: Yes, great question. Thank you. We did not have to really focus on supply. I mean don’t get me wrong. The operations team is working incredibly hard to ensure we don’t have that issue. And I very – particularly at the beginning of the quarter, I said we didn’t expect that to limit us. The real – and we’re hoping to keep ahead of that curve going forward, and the team is working diligently. As it relates to PE versus DVT, we’re not really seeing a difference. There are, obviously, competitive reactions and physicians who are going to have different viewpoints to start. But what we’re seeing is both of those areas, whether it’s PE case or DVT case are incredibly successful and physicians are responding to that. Some might start with one and then navigate to the other and vice versa.
